Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2011. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding their interests in the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details the acquisition of Ordinary shares by nine individuals on April 11, 2011, at a price of £12.29 per share through the Company's Share Reward Plan. Each individual acquired 10 shares under the partnership element (personal contribution) and 10 shares under the matching element (Company contribution), totaling 20 shares per person.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of specific share purchases in compliance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the share price of £12.29 per Ordinary share on April 11, 2011.
- Confirm the total number of shares acquired by each listed director (20 shares each).
- Review the terms of the Company's Share Reward Plan regarding personal and matching contributions.
- Note that this filing contains no financial performance metrics for the period.